Trial Profile
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs GEN 009 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Malignant melanoma; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Renal cell carcinoma; Skin cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Genocea Biosciences [CEASED]
- 15 Apr 2022 Status changed from active, no longer recruiting to completed.
- 28 Nov 2021 According to a Genocea Biosciences media release, data from this trial will be presented at Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting.
- 24 Jun 2021 Planned End Date changed from 1 Dec 2022 to 1 Mar 2022.